OncoMatch/Clinical Trials/NCT06880393
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
Is NCT06880393 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies anti-BCMA-CAR-T for multiple myeloma.
Treatment: anti-BCMA-CAR-T — This is a single-arm, open-label study to evaluate the efficacy and safety of BCMA CAR-T in dynamic high-risk patients with multiple myeloma
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA expression (confirmed expression on MM cells by flow cytometry or bone marrow immunohistochemistry)
Confirmed expression of the BCMA target antigen on MM cells by flow cytometry or bone marrow immunohistochemistry
Allowed: TP53 mutation
Relapse with new genetic abnormalities: Gain(1q), del(17p), or TP53 mutation
Prior therapy
Must have received: proteasome inhibitor — induction
Induction therapy with at least one proteasome inhibitor
Must have received: immunomodulatory agent — induction
Induction therapy with at least one immunomodulatory agent
Must have received: corticosteroid — induction
Induction therapy with...corticosteroids
Must have received: autologous hematopoietic stem cell transplantation — sequential or consolidation
Sequential autologous hematopoietic stem cell transplantation or consolidation therapy
Must have received: maintenance therapy — maintenance
Maintenance therapy based on either a proteasome inhibitor or an immunomodulatory agent
Cannot have received: BCMA-targeted therapy
Previous treatment with BCMA-targeted therapy
Cannot have received: CAR-T cell therapy
Previous treatment with...CAR-T cell therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify